$LIN

Evercore ISI Adjusts Price Target on Linde to $515 From $525, Keeps Outperform Rating

Evercore ISI lowered its price target on Linde to $515 from $525 while keeping an Outperform rating, according to the firm. The article also notes BMO Capital’s separate adjustment to $546 from $560 with an Outperform rating. The changes may affect near-term sentiment and valuation expectations for Linde shares.

Original reporting
Published Aug 11, 2026, 12:49 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 3:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$LIN
Neutral
medium confidence
Mentioned
$LIN · $EVR
Relevance
4/10
alphai data visualization · based on marketscreener.com
Decision brief

The 30-second read

$LINNeutralLow
01

Why it matters

A lower PT can pressure short-term sentiment, but a rating hold typically reduces the probability of a sustained selloff absent new fundamentals.

02

Market read

This is primarily a sentiment/valuation update rather than a new fundamental disclosure for Linde.

03

What to watch

Without details on what drove the PT change (multiple, FX, cost assumptions, or EPS revisions), traders may overreact to the headline PT number.

Relevance 4/10Novelty 3/10Timing: pre-market analyst note dated 08/11/2026

Background

The piece is a brokerage note summary reporting Evercore ISI’s updated price target and rating for Linde.

Company-level read

Ticker impact

$LINNeutralMedium confidence
Context

Evercore ISI cut Linde’s price target to $515 from $525 while keeping an Outperform rating, signaling valuation/EPS estimate recalibration.

Expected impact

Likely limited near-term impact unless other firms follow with similar target cuts or the thesis changes.

Evidence & confidence

The article provides only an analyst PT adjustment and rating hold, with no new company-specific operational or financial datapoint.

Market effects

Could marginally influence sentiment across industrial gases/large-cap industrials if PT cuts cluster, but no sector-wide catalyst is provided.

No clear regional spillover beyond US-listed large-cap sentiment.

Limited, as this is a single-firm analyst target adjustment without new global macro or regulatory developments.

Counterpoint

The maintained Outperform rating may indicate the PT cut is more about valuation math than deteriorating fundamentals, so the net signal could be closer to neutral than bearish.

Key entities

  • Linde

    Subject of the analyst price-target adjustment and rating maintenance.

  • Evercore ISI

    Brokerage issuing the updated price target to $515 from $525 and keeping Outperform.

Related articles

$EVRMed

Everpure Jumps 6.0% After Guggenheim Maintains Buy

Everpure, Inc. shares rose 6.0% to $118.05 on Thursday on analyst upgrades and higher price targets, trading about 1.3M shares. Guggenheim kept a Buy and raised its target to $150. Citigroup raised to $118 (Buy), Evercore ISI to $120 (Outperform), Susquehanna to $120, and Morgan Stanley to $108 (Overweight). Average new target: $123.

$LINMed

Linde (LIN) vs. Air Products (APD): Racing for the Chip Boom

Linde (LIN) said it won a long-term supply agreement for ultra-high-purity industrial gases to a major semiconductor manufacturer, with a $1 billion Phoenix, Arizona investment and two SPECTRA air separation units. Linde’s Taiwan JV plans about $800 million for related expansion. Linde reported Q2 sales of $9.29 billion and adjusted EPS $4.50. Air Products (APD) also won a Taiwan semiconductor-related infrastructure deal.

$LINMed

$1B Arizona project to boost gas supply for advanced chipmaking

Linde said it will invest $1 billion to expand on-site ultra-high-purity industrial gas production at a Phoenix, Arizona complex under a long-term supply agreement with an unnamed semiconductor manufacturer. The gases (nitrogen, oxygen, argon) will support two new fabrication plants. Linde LienHwa will invest about $800 million in Taiwan for industrial gas and hydrogen facilities for the same customer.

$LINMed

Linde plc Q2 2026 Earnings Call Summary

Linde plc reported record Q2 sales and near double-digit EPS growth, with a record $8.1 billion project backlog after electronics wins in the Western U.S. Operating margins excluding cost pass-through fell 30 bps due to U.S. homecare (Lincare) headwinds and a mix shift. Full-year EPS guidance raised to $17.70-$17.90; helium normalization expected early 2027.

$LINMed

Why is Linde stock sliding today?

Investing.com reports Linde shares fell about 5.9% to $478.87 after its Q2 2026 earnings release showed margin pressure despite a top and bottom line beat. Adjusted EPS was $4.50 (+10% YoY) on $9.3B sales (+9%), but adjusted operating margin fell to 29.5%. Full-year 2026 guidance stayed at $17.70–$17.90 and Q3 at $4.45–$4.55.

$LINMed

Linde to invest $1 billion in Arizona for semiconductor gases

Linde (NYSE:LIN) said it secured a long-term contract to supply ultra-high-purity industrial gases to a major semiconductor manufacturer and will invest about $1 billion in Arizona. The deal includes building, owning, and operating two air separation units to expand supply of nitrogen, oxygen, and argon for two new fabs. Linde’s Taiwan JV plans about $800 million for the same customer.